ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 38 citations in OpenAlex.
- Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.The Journal of clinical investigation · 2011Trial
- The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.Frontiers in immunology · 2024Review
- Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse.Frontiers in immunology · 2022Observational
- Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.Cancer treatment and research · 2022Article
- EXOSC5 promotes proliferation of gastric cancer through regulating AKT/STAT3 signaling pathways.Journal of Cancer · 2022Article
- Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy.Cell reports · 2021Article
- 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.Cancer research · 2021Review
- Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3Frontiers in oncology · 2021Article
- Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation.Immuno-oncology technology · 2020Review
- T cell optimization for graft-versus-leukemia responses.JCI insight · 2020Review
- Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2019Review
- NUDCD1 promotes metastasis through inducing EMT and inhibiting apoptosis in colorectal cancer.American journal of cancer research · 2018Article
- NudCD1 affects renal cell carcinoma through regulating LIS1/Dynein signaling pathway.American journal of translational research · 2018Article
- Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Immunological off-target effects of imatinib.Nature reviews. Clinical oncology · 2016Review
- New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.Bone marrow transplantation · 2016Review
- Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.Leukemia · 2015Review
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Blood · 2014Article
- Article
- Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.Blood cancer journal · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
purposeThe target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. EXPERIMENTAL
designWe examined responses developing against CML66, an immunogenic antigen preferentially expressed in myeloid progenitor cells identified from a patient with chronic myelogenous leukemia who attained long-lived remission following CD4+ donor lymphocyte infusion (DLI).
resultsFrom this patient, CML66-reactive CD8+ T-cell clones were detected against an endogenously presented HLA-B*4403-restricted epitope (HDVDALLW). Neither CML66-specific antibody nor T-cell responses were detectable in peripheral blood before DLI. However, by 1 month after DLI, CD8+ T cells were present in peripheral blood and at 10-fold higher frequency in marrow. Subsequently, plasma antibody to CML66 developed in association with disease remission. Donor-derived CML66-reactive T cells were detected at low levels in vivo in marrow before DLI by ELISpot and by a nested PCR-based assay to detect clonotypic T-cell receptor sequences but not in blood of the patient pre-DLI nor of the graft donor.
conclusionsCD4+ DLI results in rapid expansion of preexisting marrow-resident leukemia-specific donor CD8+ T cells, followed by a cascade of antigen-specific immune responses detectable in blood. Our single-antigen analysis thus shows that durable posttransplant tumor immunity is directed in part against nonpolymorphic overexpressed leukemia antigens that elicit coordinated cellular and humoral immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.